Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2019-000904-14 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate whether adult participants with moderate to severe plaque psoriasis who have been treated with secukinumab or ixekizumab for at least 6 months and are experiencing a suboptimal response may benefit from switching to risankizumab with regard to skin symptoms, quality of life symptoms and psoriasis symptoms.
Study duration will last for up to 64 weeks with risankizumab given by subcutaneous injection at Week 0, Week 4, and then every 12 weeks for 52 Weeks (With the last dose being administered at Week 40). An additional visit will occur at Week 8 for a physical exam and questionnaire collection. A final follow-up phone call will occur at Week 60.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Risankizumab | Other | Participants receive Risankizumab following suboptimal response to secukinumab or ixekizumab |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Risankizumab | Drug | Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1 | The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. | At Week 16 |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Participants Achieving a sPGA Clear Response (sPGA 0) | The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. | At Week 16 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alliance Dermatology and MOHs /ID# 216001 | Phoenix | Arizona | 85032 | United States | ||
| Burke Pharmaceutical Research /ID# 225023 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39516454 | Derived | Warren RB, Pavlovsky L, Costanzo A, Bukhalo M, Korman NJ, Huang YH, Kokolakis G, Pinter A, Ibrahim N, Zheng Y, Drogaris L, Stakias V, Soliman AM, Rubant S, Thaci D. Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study. Dermatol Ther (Heidelb). 2024 Dec;14(12):3273-3290. doi: 10.1007/s13555-024-01292-z. Epub 2024 Nov 8. |
| Label | URL |
|---|---|
| Related info | View source |
Not provided
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Not provided
Significant site non-compliance for this study was identified at one site since interim results were posted. As a result of this finding, participants enrolled in this trial site were not included in any final analysis. Adverse events or lab abnormalities were reported in 1 participant from this site. The participant was on risankizumab and had a non serious event of headache (assessed as mild), which did not lead to study drug discontinuation
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Risankizumab | Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS) |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jan 27, 2021 | Jan 11, 2023 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1 |
The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life. |
| At Week 16 |
| Proportion of Participants Achieving a Psoriasis Symptoms Scale (PSS) 0 | The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe). | At Week 16 |
| Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1 | The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. | At Week 52 |
| Proportion of Participants Achieving a sPGA Clear Response (sPGA 0) | The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. | At Week 52 |
| Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1 | The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life. | At Week 52 |
| Proportion of Participants Achieving a PSS 0 | The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe). | At Week 52 |
| Time to Achieve sPGA 0/1 | The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. | Up to Week 52 |
| Time to Achieve sPGA 0 | The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. | Up to Week 52 |
| Hot Springs |
| Arkansas |
| 71913-6404 |
| United States |
| Arkansas Research Trials /ID# 225497 | North Little Rock | Arkansas | 72117 | United States |
| Bakersfield Derma & Skin Cance /ID# 213480 | Bakersfield | California | 93309 | United States |
| UC Davis Health /ID# 225367 | Sacramento | California | 95816-3300 | United States |
| CCD Research, PLLC /ID# 216062 | Cromwell | Connecticut | 06416-1745 | United States |
| Florida International Rsrch cr /ID# 224983 | Miami | Florida | 33173 | United States |
| Advanced Medical Research /ID# 213484 | Sandy Springs | Georgia | 30328-6141 | United States |
| Arlington Dermatology /ID# 216000 | Rolling Meadows | Illinois | 60008 | United States |
| Dawes Fretzin, LLC /ID# 216004 | Indianapolis | Indiana | 46256 | United States |
| DermAssociates-Rockville /ID# 213837 | Rockville | Maryland | 20850 | United States |
| Cleaver Dermatology /ID# 226137 | Kirksville | Missouri | 63501-5362 | United States |
| Central Dermatology, PC /ID# 213479 | St Louis | Missouri | 63117 | United States |
| University Hospitals Case Medical Center /ID# 214795 | Cleveland | Ohio | 44106 | United States |
| University of Pittsburgh MC /ID# 225644 | Pittsburgh | Pennsylvania | 15260 | United States |
| Clinical Partners, LLC /ID# 213836 | Johnston | Rhode Island | 02919 | United States |
| Arlington Research Center, Inc /ID# 215526 | Arlington | Texas | 76011 | United States |
| Bellaire Dermatology /ID# 225486 | Bellaire | Texas | 77401 | United States |
| Modern Research Associates, PL /ID# 213835 | Dallas | Texas | 75231 | United States |
| Menter Dermatology Res Inst /ID# 214002 | Dallas | Texas | 75246 | United States |
| St George Dermatology & Skin Cancer Centre /ID# 213888 | Kogarah | New South Wales | 2217 | Australia |
| Veracity Clinical Research /ID# 213889 | Woolloongabba | Queensland | 4102 | Australia |
| Skin Health Institute Inc /ID# 213886 | Carlton | Victoria | 3053 | Australia |
| Fremantle Dermatology /ID# 213887 | Fremantle | Western Australia | 6160 | Australia |
| Universitaetsklinikum Erlangen /ID# 214228 | Erlangen | Bavaria | 91054 | Germany |
| Universitaetsklinikum Frankfurt /ID# 215889 | Frankfurt am Main | Hesse | 60590 | Germany |
| Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 215691 | Berlin | 10117 | Germany |
| Klinikum Ruhr Univ Bochum /ID# 225473 | Bochum | 44791 | Germany |
| Universitaetsklinikum Schleswig-Holstein Campus Luebeck /ID# 214469 | Lübeck | 23538 | Germany |
| Dermatologische Gemeinschaftspraxis Mahlow /ID# 225472 | Mahlow | 15831 | Germany |
| Beldio Research GmbH /ID# 225471 | Memmingen | 87700 | Germany |
| Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 214506 | Munich | 81675 | Germany |
| The Chaim Sheba Medical Center /ID# 213815 | Ramat Gan | Tel Aviv | 5265601 | Israel |
| Tel Aviv Sourasky Medical Center /ID# 213812 | Tel Aviv | Tel Aviv | 6423906 | Israel |
| HaEmek Medical Center /ID# 214059 | Afula | 1834111 | Israel |
| Rabin Medical Center /ID# 213813 | Petah Tikva | 4941492 | Israel |
| Istituto Clinico Humanitas /ID# 214749 | Rozzano | Milano | 20089 | Italy |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 214745 | Bologna | 40138 | Italy |
| Azienda Ospedaliero Universitaria di Cagliari- Presidio Ospedaliero /ID# 214748 | Cagliari | 09124 | Italy |
| Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 214750 | Milan | 20122 | Italy |
| Azienda Ospedaliero-Universitaria di Modena /ID# 214751 | Modena | 41124 | Italy |
| AOU Universita degli Studi della Campania Luigi Vanvitelli /ID# 214752 | Naples | 80138 | Italy |
| Hospital Universitario Germans Trias i Pujol /ID# 214031 | Badalona | Barcelona | 08916 | Spain |
| Hospital Universitario Fundacion Alcorcon /ID# 214033 | Alcorcón | Madrid | 28922 | Spain |
| Hospital Parc de Salut del Mar /ID# 214034 | Barcelona | 08003 | Spain |
| Hospital Puerta del Mar /ID# 214428 | Cadiz | 11009 | Spain |
| Hospital Universitario La Paz /ID# 214341 | Madrid | 28046 | Spain |
| Hospital Universitario y Politecnico La Fe /ID# 214032 | Valencia | 46026 | Spain |
| Chung Shan Medical University Hospital /ID# 213634 | Taichung | 40201 | Taiwan |
| National Taiwan University Hospital /ID# 213630 | Taipei | 100 | Taiwan |
| MacKay Memorial Hospital /ID# 213845 | Taipei | 10449 | Taiwan |
| Linkou Chang Gung Memorial Hospital /ID# 213631 | Taoyuan City | 333 | Taiwan |
| Victoria Hospital /ID# 213881 | Kirkcaldy | Fife | KY2 5AH | United Kingdom |
| Russells Hall Hospital, Dudley /ID# 213878 | Dudley | DY1 2HQ | United Kingdom |
| Leeds Teaching Hospitals NHS Trust /ID# 213880 | Leeds | LS9 7TF | United Kingdom |
| The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 213877 | Newcastle upon Tyne | NE7 7DN | United Kingdom |
| Northern Care Alliance NHS Group /ID# 213873 | Salford | M6 8HD | United Kingdom |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Risankizumab | Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Age, Customized | Count of Participants | Participants |
| |||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| |||||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1 | The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. | Intent-to-Treat (ITT) Population, which is defined as all subjects who had at least 1 dose of study drug | Posted | Count of Participants | Participants | At Week 16 |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Proportion of Participants Achieving a sPGA Clear Response (sPGA 0) | The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. | Intent-to-Treat (ITT) Population, which is defined as all subjects who had at least 1 dose of study drug | Posted | Count of Participants | Participants | At Week 16 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1 | The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life. | Intent-to-Treat (ITT) Population, which is defined as all subjects who had at least 1 dose of study drug | Posted | Count of Participants | Participants | At Week 16 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Proportion of Participants Achieving a Psoriasis Symptoms Scale (PSS) 0 | The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe). | Intent-to-Treat (ITT) Population, which is defined as all subjects who had at least 1 dose of study drug | Posted | Count of Participants | Participants | At Week 16 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1 | The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. | Intent-to-Treat (ITT) Population, which is defined as all subjects who had at least 1 dose of study drug | Posted | Count of Participants | Participants | At Week 52 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Proportion of Participants Achieving a sPGA Clear Response (sPGA 0) | The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. | Intent-to-Treat (ITT) Population, which is defined as all subjects who had at least 1 dose of study drug | Posted | Count of Participants | Participants | At Week 52 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) 0/1 | The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life. | Intent-to-Treat (ITT) Population, which is defined as all subjects who had at least 1 dose of study drug | Posted | Count of Participants | Participants | At Week 52 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Proportion of Participants Achieving a PSS 0 | The PSS is a 4-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis (Appendix 8.2). The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed as a daily diary, using a 5-point scale ranging from 0 (none) to 4 (very severe). | Intent-to-Treat (ITT) Population, which is defined as all subjects who had at least 1 dose of study drug | Posted | Count of Participants | Participants | At Week 52 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Time to Achieve sPGA 0/1 | The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. | Intent-to-Treat (ITT) Population, which is defined as all subjects who had at least 1 dose of study drug | Posted | Number | 95% Confidence Interval | Days | Up to Week 52 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Time to Achieve sPGA 0 | The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. | Intent-to-Treat (ITT) Population, which is defined as all subjects who had at least 1 dose of study drug | Posted | Number | 95% Confidence Interval | Days | Up to Week 52 |
|
|
From Baseline Day 1 up to Week 52
The Safety Analysis Set, which is defined as all subjects who received at least one dose of study drug in Study M19-164, was used for all safety analyses. In this study, the Safety Analysis Set is the same as the ITT population.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Risankizumab | Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS) | 0 | 244 | 17 | 244 | 31 | 244 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| CORONARY ARTERY DISEASE | Cardiac disorders | MedDRA 25.0 | Systematic Assessment |
| |
| MYOCARDIAL INFARCTION | Cardiac disorders | MedDRA 25.0 | Systematic Assessment |
| |
| LARGE INTESTINAL HAEMORRHAGE | Gastrointestinal disorders | MedDRA 25.0 | Systematic Assessment |
| |
| OEDEMATOUS PANCREATITIS | Gastrointestinal disorders | MedDRA 25.0 | Systematic Assessment |
| |
| OESOPHAGEAL VARICES HAEMORRHAGE | Gastrointestinal disorders | MedDRA 25.0 | Systematic Assessment |
| |
| CHOLELITHIASIS | Hepatobiliary disorders | MedDRA 25.0 | Systematic Assessment |
| |
| APPENDICITIS | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
| |
| DIVERTICULITIS | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
| |
| POSTOPERATIVE WOUND INFECTION | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
| |
| MULTIPLE INJURIES | Injury, poisoning and procedural complications | MedDRA 25.0 | Systematic Assessment |
| |
| MUSCULAR WEAKNESS | Musculoskeletal and connective tissue disorders | MedDRA 25.0 | Systematic Assessment |
| |
| OSTEOARTHRITIS | Musculoskeletal and connective tissue disorders | MedDRA 25.0 | Systematic Assessment |
| |
| NON-SMALL CELL LUNG CANCER | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 25.0 | Systematic Assessment |
| |
| APHASIA | Nervous system disorders | MedDRA 25.0 | Systematic Assessment |
| |
| EPILEPSY | Nervous system disorders | MedDRA 25.0 | Systematic Assessment |
| |
| ACUTE KIDNEY INJURY | Renal and urinary disorders | MedDRA 25.0 | Systematic Assessment |
| |
| FIBULA FRACTURE | Injury, poisoning and procedural complications | MedDRA 25.0 | Systematic Assessment |
| |
| HAND FRACTURE | Injury, poisoning and procedural complications | MedDRA 25.0 | Systematic Assessment |
| |
| PROSTATE CANCER STAGE I | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 25.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| NASOPHARYNGITIS | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA 25.0 | Systematic Assessment |
|
AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Global Medical Services | AbbVie | 800-633-9110 | abbvieclinicaltrials@abbvie.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jul 31, 2023 | Nov 2, 2023 | SAP_002.pdf |
Not provided
| ID | Term |
|---|---|
| C000601773 | risankizumab |
Not provided
Not provided
Not provided
| ≥ 65 years |
|
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Italy |
|
| Spain |
|
| United Kingdom |
|
| Israel |
|
| Australia |
|
| Taiwan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|